Medical/Pharmaceuticals
NECC Selects MedMinder to Transform Their Medication Management for Individuals with Autism They Serve
NORWOOD, Mass., July 3, 2025 /PRNewswire/ -- The New England Center for Children (NECC), a globally recognized leader in autism education and research, has contracted with MedMinder, to enhance the safety, consistency, and reliability of medication management across its programs. The collaborati...
2025-07-04 01:52
1968
Fangzhou Tops China's App Store Chart for Healthcare Apps
GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in theJune 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by ...
2025-07-03 18:43
2110
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment ofMaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZ...
2025-07-03 18:07
2103
Esaote presents at ECVS 2025 the new generation of veterinary MRI, Vet -MR Grande ELITE
GENOA, Italy and ANTWERP, Belgium, July 3, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, presents the new Vet -MR Grande ELITE, the next generation of veterinary MRIat the ECVS 2025, the Annual scientific meeting of European College of Veterinary Surge...
2025-07-03 18:00
2508
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...
2025-07-03 14:46
2179
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to a...
2025-07-03 13:30
2069
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...
2025-07-03 08:08
2176
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
2187
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have been dosed in a U.S. 13-week Phase IIa study of small m oleculeoral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction f...
2025-07-03 07:00
2113
SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response
SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinic...
2025-07-02 23:00
2016
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of V...
2025-07-02 21:00
2239
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
* Gram-negative bacterial infections are becoming an increasingly serious global health issue * U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 * Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON ...
2025-07-02 20:00
1893
Bon Announces Breakthrough Order for $16 Million Gut-Health Products
XI'AN, China, July 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health, and personal care industries, today announced a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Te...
2025-07-02 20:00
3805
Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. andAsia, Arbele stood out for its groundbr...
2025-07-02 16:19
1614
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up. * The updated data showed that EVER001 was well-tolerated and efficacious ...
2025-07-02 15:33
2054
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
* BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market * New board leadership reflects Field's momentum and readiness for pivotal execution CARDIFF-BY-THE-SEA, Calif., July 1, 2025 /PRNewswire/ -- Fi...
2025-07-01 22:47
2484
TraceLink's MINT Named "Supply Chain Transparency Solution of the Year" in 2025 SupplyTech Breakthrough Awards
The award recognizes MINT for enabling real-time, end-to-end visibility across critical supply chain transactions and processes BOSTON, July 1, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that its Mu...
2025-07-01 22:42
2317
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
* Real-time analytics that empower clinical decision-making and pandemic preparedness * Global unveiling at ADLM 2025 in Chicago to initiate business partnerships * Powered by AI and syndromic PCR to enable early detection and predictive insights SEOUL, South Korea, July 1, 2025 /PRNewswire/...
2025-07-01 22:09
2690
FAIR PLAY MENARINI INTERNATIONAL AWARD, LUIS FIGO JOINS THE GREAT SPORTS STARS ACKNOWLEDGED IN 2025
FLORENCE, Italy, July 1, 2025 /PRNewswire/ -- Surprises never end when it comes to theFair Play Menarini International Award: Luís Figo, European football legend and true icon of sporting integrity, will be among the awardees of the 29th edition of the event, taking place onJuly 2nd and 3rd in Fl...
2025-07-01 21:10
2552
Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes MORRISVILLE, N.C., July 1, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, d...
2025-07-01 21:00
1834
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 271 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27